Baxter International Inc. filed a Form 8-K on November 19, 2026, disclosing a Stockholder Engagement Presentation for the fourth quarter of 2026. The document outlines the company's strategic priorities, leadership changes, and updated financial guidance.

The presentation details progress made during the first year of Andrew Hider’s tenure as President and CEO. Management has focused on three pillars: stabilizing the business, strengthening the balance sheet, and driving continuous improvement. To support stronger coordination, the company combined Pharmaceuticals and Infusion Therapies into a single segment. Operations were also simplified by discontinuing the manufacturing of cephalosporin products at the Round Lake, Illinois injectables facility.

Regarding financial performance, Baxter raised its full-year 2026 organic sales guidance to a range of +3% to +4%. The company reported year-to-date free cash flow of $705 million. On the balance sheet, Baxter completed a $600 million cash tender offer that retired $864 million of debt. The company is currently on track to achieve a net leverage target of approximately 3.0x by the end of the year.

In leadership updates, John Rogers was appointed as EVP and CFO effective October 1, 2026. The Board of Directors structure was also enhanced, with Brent Shafer appointed as Non-Executive Chair to separate the CEO and Chair roles. Additionally, Michael McDonnell was appointed to the Board and Audit Committee in February 2026.

The company also updated its sustainability strategy, guided by a double materiality assessment. New forward-looking targets were established, including a commitment to net-zero Scope 1 and Scope 2 greenhouse gas emissions by 2050 and 100% renewable electricity by 2040. In 2025, Baxter established the inaugural Chief Sustainability Officer role to strengthen governance in this area.